ProSight developed a novel modality in prostate cancer. Our invention – based on knowhow from the Weizmann Institute of Science – allows workflow-neutral use of the hallmark biomarker of prostate cancer in the clinical flow, potentially doubling detection-rate and cancer-grading accuracy. Successful clinical study with a prototype; one granted patent, one pending; article published; plans for FDA 510(k) in 18 months and launching in two years. Sectors Medical equipment and supplies Location Israel Stage Sign in to view details Markets Sign in to view details Customer model Sign in to view details Contact Sign in to view details Social media